Zydus Cadila gets final approval from USFDA for Ziprasidone Hydrochloride Capsules

23 Aug 2017 Evaluate

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Ziprasidone Hydrochloride Capsules in strengths of 20 mg, 40 mg, 60 mg, and 80 mg.  Ziprasidone, an antipsychotic medication, is used to treat schizophrenia and the manic symptoms of bipolar disorder (manic depression). The drug will be manufactured at the group's formulations manufacturing facility at the Phanna SEZ, Ahmedabad. 

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

913.90 -7.35 (-0.80%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×